You are here: Home > News > Canadian Company expands to Leipzig



Canadian Company expands to Leipzig

Canadian Company expands to Leipzig

The canadian pharmaceutical company Nuvo Research Inc. establishes a branch in Leipzig. Research program encompasses drug development for allergic rhinitis and rheumatoid arthritis.

The Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig and the Canadian pharmaceutical and biotech company Nuvo Research Inc. have initiated a cooperative project in drug development. The cooperation will be funded by the Development Bank of Saxony (Sächsische Aufbaubank SAB). The grant approval was personally handedover by Saxony's Economics Minister Thomas Jurk on August 20, 2009 in the context of a press conference at the Fraunhofer Institute Leipzig to Dr. Wilhelm Gerdes from the Fraunhofer Institute, and Dr. Henrich Guntermann, President & CEO of Nuvo Research Inc..

The granted funding shall support the preclinical and clinical development of an immune modulating drug in the Leipzig location. Nuvo Research GmbH, a subsidiary company of the Canadian company which was established specifically for this purpose in Leipzig, will expedite the development of the drug WF10 with local partners. The activities will be planned and coordinated by employees of the company in Leipzig.
Nuvo Research GmbH Leipzig plans to recruit up to 15 new employees, primarily in the area of the clinical development of the drug WF10. The approved SAB project extends over three years with a total volume of over one million Euro.

Nuvo Research Inc. in Canada is focused on the development of topical, transdermal and immunmodulatory technologies. In the area of pain therapy and wound healing two drugs have already received multinational authorization. Nuvo Research Inc., listed on the Canadian stock exchange, carries out Research & Development and manufactures drug products in its branches Canada (Toronto, Montreal), USA (San Diego) and Germany (Wanzleben). The new Nuvo Research branch in Leipzig offers the advantage of short communication channels to development partners and service providers and allows rapid development of WF10.

The Fraunhofer-Gesellschaft undertakes applied research of direct utility to private and public enterprise and of wide benefit to society.

The Fraunhofer Institute for Cell Therapy and Immunology IZI is member of the Fraunhofer Group for Life Sciences. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.

Dr. Wilhelm Gerdes
Phone +49 (0) 341/355 36-9300
Fax +49 (0) 341/355 36-9912

Fraunhofer-Institut für Zelltherapie und Immunologie
Perlickstraße 1
04103 Leipzig

Telefon +49 (0) 341/355 36-1000
Fax +49 (0) 341/355 36-9921

Document Actions